​

Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HALO Stock Forecast

Halozyme Therapeutics (HALO) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $110.00, with a high of $130.00 and a low of $90.00. This represents a -11.67% decline from the last price of $124.54.

$60 $74 $88 $102 $116 $130 High: $130 Avg: $110 Low: $90 Last Closed Price: $124.54

HALO Stock Rating

Halozyme Therapeutics stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (66.67%), 8 Hold (29.63%), 1 Sell (3.70%), and 0 Strong Sell (0.00%).

Buy
Total 27 1 8 18 Strong Sell Sell Hold Buy Strong Buy

HALO Price Target Upside V Benchmarks

TypeNameUpside
StockHalozyme Therapeutics-11.67%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2616
Avg Price Target$130.00$114.17$94.19
Last Closing Price$124.54$124.54$124.54
Upside/Downside4.38%-8.33%-24.37%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26252--9
Sep, 26252--9
Aug, 26243--9
Jul, 262431-10
Jun, 262431-10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2026Stifel Nicolaus$130.00$121.516.99%4.38%
Oct 08, 2026Mitchell KapoorH.C. Wainwright$130.00$110.7917.34%4.38%
Aug 10, 2026Wells Fargo$95.00$103.12-7.87%-23.72%
Aug 07, 2026Sean LaamanMorgan Stanley$105.00$98.156.98%-15.69%
Aug 07, 2026Leerink Partners$110.00$85.7628.26%-11.67%
Aug 07, 2026H.C. Wainwright$115.00$85.7634.10%-7.66%
Jun 03, 2026UBS$90.00$68.7830.85%-27.73%
May 12, 2026Morgan Stanley$93.00$71.1130.78%-25.33%
Apr 29, 2026Mitchell KapoorH.C. Wainwright$95.00$63.8648.76%-23.72%
Apr 21, 2026Morgan Stanley$96.00$69.5737.99%-22.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.BuyBuyhold
Oct 07, 2026H.C. WainwrightBuyBuyhold
Sep 02, 2026H.C. WainwrightBuyBuyhold
Aug 07, 2026Morgan StanleyOverweightOverweighthold
Aug 07, 2026Cowen & Co.BuyBuyhold
Aug 07, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 07, 2026CitigroupOutperformOutperformhold
Aug 07, 2026H.C. WainwrightBuyBuyhold
Jul 21, 2026BenchmarkBuyBuyhold
Jun 16, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.86$1.48$2.13$3.50$2.64---
Avg Forecast$2.68$1.32$2.77$4.13$5.05$6.92$8.33$8.84
High Forecast$2.76$1.41$2.79$4.19$5.35$7.86$8.54$9.06
Low Forecast$2.62$1.28$2.74$4.08$4.72$6.24$7.90$8.63
Surprise %6.72%12.12%-23.10%-15.25%-47.72%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$443.31M$660.12M$829.25M$1.02B$1.40B---
Avg Forecast$443.24M$671.79M$830.53M$1.00B$1.19B$1.47B$1.71B$1.83B
High Forecast$453.46M$708.75M$838.20M$1.02B$1.21B$1.47B$1.72B$1.87B
Low Forecast$434.71M$658.04M$827.36M$990.77M$1.18B$1.46B$1.71B$1.80B
Surprise %0.02%-1.74%-0.15%1.18%17.69%---

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$402.71M$202.13M$281.59M$444.09M$316.89M---
Avg Forecast$279.99M$331.72M$281.59M$554.68M$675.23M$946.10M$1.10B$1.19B
High Forecast$335.99M$398.06M$337.91M$562.06M$717.60M$1.05B$1.15B$1.22B
Low Forecast$224.00M$265.38M$225.28M$547.30M$632.86M$837.53M$1.06B$1.16B
Surprise %43.83%-39.07%--19.94%-53.07%---

HALO Forecast FAQ

Is Halozyme Therapeutics stock a buy?

Halozyme Therapeutics stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Halozyme Therapeutics is a favorable investment for most analysts.

What is Halozyme Therapeutics's price target?

Halozyme Therapeutics's price target, set by 27 Wall Street analysts, averages $110 over the next 12 months. The price target range spans from $90 at the low end to $130 at the high end, suggesting a potential -11.67% change from the previous closing price of $124.54.

How does Halozyme Therapeutics stock forecast compare to its benchmarks?

Halozyme Therapeutics's stock forecast shows a -11.67% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Halozyme Therapeutics over the past three months?

  • October 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 22.22% Strong Buy, 44.44% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Halozyme Therapeutics’s EPS forecast?

Halozyme Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $6.92, marking a 162.12% increase from the reported $2.64 in 2025. Estimates for the following years are $8.33 in 2027, and $8.84 in 2028.

What is Halozyme Therapeutics’s revenue forecast?

Halozyme Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.47B, reflecting a 4.91% increase from the reported $1.4B in 2025. The forecast for 2027 is $1.71B, and $1.83B for 2028.

What is Halozyme Therapeutics’s net income forecast?

Halozyme Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $946.1M, representing an 198.56% increase from the reported $316.89M in 2025. Projections indicate $1.1B in 2027, and $1.19B in 2028.